Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Waldenstrom Macroglobulinemia therapeutics.

Synopsis

• In 2022, there will be more than 14,000 incident cases of WM across 16 pharmaceutical markets.
• There are three leading marketed drugs for the treatment of WM, and Beigene is a key player in the disease space.
• A total of six pipeline drugs for WM are in late-stage (Phase III and Pre-registration) development.
• Commercial sponsors dominate clinical trial development in WM, with the US emerging as the key countries for conducting trials in WM.
• Deals involving partnerships were the most common type of deals globally, except in South America.
• Therapeutic options for WM patients continue to be limited, and no new therapy is expected to reach the US market in the next 12 months.

Scope

GlobalData’s combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type and Route of Administration
• Product Profiles with Sales Forecast
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Waldenstrom Macroglobulinemia market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Waldenstrom Macroglobulinemia market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.